Le Lézard
Classified in: Health
Subjects: PDT, TDS, FVT

Glooko's diasend Diabetes Data Platform to Unveil Greater Connectivity and System Enhancements at EASD Meeting in Barcelona


New third-party app connections, more compatible devices and in-clinic Bluetooth uploads to better connect patients and their data with clinicians

MOUNTAIN VIEW, California and GOTHENBURG, Sweden, Sept. 17, 2019 /PRNewswire/ -- Glooko®, the leader in diabetes data management solutions, continues to strengthen its global position with the introduction of several new features and expanded connectivity capabilities for the diasend® by Glooko system at this week's 55th annual meeting of the European Association for the Study of Diabetes (EASD). The additional device integration partnerships, new ways to upload patient data in clinic, and feature enhancements will be unveiled at the September 17-20 meeting in Barcelona.

Increased device compatibility

At EASD, Europe's largest and most prominent diabetes meeting, Glooko will share new device integrations it has developed with two new partners:

Additional ways to upload data in-clinic

At the beginning of 2019, NFC connectivity (near-field communication) was introduced in the hardware of the diasend® by Glooko system, which serves as a "one-stop shop" for patients when visiting their health care provider, because it's able to upload data from numerous devices regardless of brand. Now, BLE (Bluetooth Low Energy) is also added to the mix of ways to upload data to the diasend® solution, providing greater flexibility for the upload process and making clinic/patient interaction even easier. Both NFC and BLE are expected to become increasingly common in diabetes devices during the next couple of years.

"Glooko is pleased to bring additional value to our customers with new data solutions and device integrations on our trusted diasend data management platform," said Russ Johannesson, CEO of Glooko. "It exemplifies the increasing momentum of Glooko solutions, which provide comprehensive patient-based diabetes data to physicians, better connecting them with their patients. Our greater reach with diasend by Glooko enables healthcare professionals to better focus on value-based outcomes for the patients they serve."

Prominent speakers at EASD

On the scientific front, Glooko will offer in-booth presentations from two renowned speakers:

"We are proud of the array of diasend by Glooko news that will be showcased at EASD this year, and how it highlights our continuous innovation. We are adding more options to our comprehensive list of compatible devices and introducing new ways for them to function seamlessly with our universal solution," said Anders Sonesson, Global VP and General Manager of Glooko.  "As always, we put our users at the heart of everything we do, and these additions will facilitate the patient/clinic interaction from both sides."

*Available in selected European countries.

About Glooko
Glooko's universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world's leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000+ clinic locations in 24 countries across 15 languages. Learn more by visiting www.glooko.com 

Media Contacts:

Sebastian Persson
Marketing Director EMEA/APAC
sebastian.persson@glooko.com
+46 701 46 10 10

Jeff Christensen
SignalWest Public Relations
+1 831-566-0275
Jeff@SignalWestPR.com

 


These press releases may also interest you

at 01:13
Moberg Pharma AB (OMX: MOB) has signed a distribution agreement with DongKoo Bio & Pharma Co., Ltd for MOB-015 in the Republic of Korea. Under the agreement DongKoo is granted exclusive rights to market and sell MOB-015 in the Republic of Korea....

at 01:05
Sartorius, a leading international partner of biopharmaceutical research and the industry, performed dynamically in the third quarter as well, achieving double-digit growth rates in sales revenue, order intake and earnings in the first nine months....

at 01:05
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced results from a retrospective chart review study (EVOLVE), which investigated the likelihood of serious adverse events and serious infections with vedolizumab and...

at 01:05
Sartorius, a leading partner to the biopharmaceutical industry and laboratories, has signed an agreement to acquire parts of Danaher's Life Science portfolio for approximately $750 million in cash. The businesses had combined sales turnover of...

at 01:05
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMbrave150 study, evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable...

at 00:10
Verseau Therapeutics, Inc. ("Verseau") launched today with $50 million in financing from 20/20 HealthCare Partners, 3SBio, Alexandria Venture Investments, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research and Yonghua...



News published on 17 september 2019 at 01:34 and distributed by: